12 Building on these results, the SCALE Maintenance trial demonstrated that the combination of liraglutide 3.0 mg per day and lifestyle intervention significantly improved weight maintenance at 56 weeks when compared with controls (who received placebo and lifestyle intervention) in overweight and obese individuals who had already lost at least 5% of initial body weight during a low-calorie diet prior to randomization
Notably, in high-quality large RCTs, tirzepatide demonstrated greater effectiveness than GLP-1R mono agonists in reducing serum glucose, fat mass, and body weight
Swirl or roll the vial gently until both peptides fully dissolve don't shake
Kolevzon A, Angarita B, Bush L, Wang AT, Frank Y, Yang A, et al
Timing: Evening administration recommended